Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1

▤ Summary

Belite Bio completed the rolling submission of its New Drug Application to the U.S. FDA for tinlarebant. The submission targets Stargardt disease type 1, a rare inherited retinal disorder. This marks a regulatory milestone for the company and advances the drug toward potential review and approval. The item is relevant to life sciences but does not describe a software product or software-company event.

▦ Linked Companies